Cyclophosphamide Diminishes Inflammation and Prolongs Transgene Expression Following Delivery of Adenoviral Vectors to Mouse Liver and Lung
- 20 August 1996
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 7 (13) , 1555-1566
- https://doi.org/10.1089/hum.1996.7.13-1555
Abstract
Immune responses to adenovirus-mediated gene transfer contribute to the problems of transient recombinant gene expression, inflammation, and difficulties with vector readministration. Activation of CD4+ T cells is required for full realization of effector function of both CD8+ T cells (i.e., cytotoxic T cells) and B cells (i.e., neutralizing antibody). We evaluate in this study the effectiveness of a short course of high-dose cyclophosphamide to block immune responses in mice administered vector into lung and liver of C57BL/6 mice. Administration of cyclophosphamide with vector directed to liver blocked activation and mobilization of both CD4+ and CD8+ T cells. As a result, transgene expression was prolonged, inflammation was reduced, and, at the higher doses of cyclophosphamide, formation of neutralizing antibody was prevented and the vector was successfully readministered. Similar studies in the lung demonstrated an effective blockade of T and B cell responses. In contrast to the liver, where it was easier to stabilize transgene expression than to prevent neutralizing antibody, cyclophosphamide prevented the formation of neutralizing antibodies at all doses in the lung, whereas stabilization of transgene expression was only achieved at the highest dose. These experiments begin to define the parameters by which cyclophosphamide could be used as an adjunct in gene therapy. Immune responses to adenoviral vectors have complicated their successful application in the treatment of chronic disorders. The initial activation of T cells to the virus is necessary for the development of cellular and humoral immunity. This study presents a strategy for preventing the initial activation of T cells by administering with the vector the cytotoxic and immune-suppressive drug cyclophosphamide. The utility of transient immune modulation is evaluated in mouse models of lung- and liver-directed gene transfer.Keywords
This publication has 15 references indexed in Scilit:
- Transfer of Genes to Humans: Early Lessons and Obstacles to SuccessScience, 1995
- Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiencyNature Medicine, 1995
- Long–term hepatic adenovirus–mediated gene expression in mice following CTLA4Ig administrationNature Genetics, 1995
- Gene Therapy for Hemophilia B: Host Immunosuppression Prolongs the Therapeutic Effect of Adenovirus-Mediated Factor IX ExpressionHuman Gene Therapy, 1995
- Oral therapy for small cell lung cancerLung Cancer, 1995
- Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosisCurrent Opinion in Rheumatology, 1995
- Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.Proceedings of the National Academy of Sciences, 1995
- Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.Proceedings of the National Academy of Sciences, 1994
- Assessment of Recombinant Adenoviral Vectors for Hepatic Gene TherapyHuman Gene Therapy, 1993
- Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus VectorHuman Gene Therapy, 1990